Cosunter(SZ:300436) Zheng Quan Shi Bao Wang·2025-09-01 11:59Core Viewpoint - Guangshentang (300436) announced a capital increase and equity transfer for its subsidiary Guangsheng Zhonglin to enhance funding for innovative drug development and operations [1][2] Group 1: Equity Transfer and Capital Increase - Guangsheng Zhonglin plans to introduce significant investors through a cash transaction totaling 250 million yuan, with Jinan Taishen and Huaxin Shiheng subscribing to new registered capital [1] - Jinan Taishen will acquire equity from existing shareholders, specifically from the core employee holding platforms, for a total transaction amount of approximately 58.65 million yuan [1][2] - Following the transaction, Guangsheng Zhonglin's registered capital will increase from 389 million yuan to 418 million yuan, and Guangshentang's ownership will decrease from 81.08% to 75.32% [1] Group 2: Innovative Drug Development - Guangsheng Zhonglin is developing innovative drugs for hepatitis treatment, with GST-HG131 and GST-HG141 included in the breakthrough therapy list by the National Medical Products Administration [2] - The ongoing clinical trials for GST-HG141 are in Phase III, while the combination therapy of GST-HG131 and GST-HG141 is in Phase II, indicating strong clinical potential [2] - The transaction is expected to enhance Guangsheng Zhonglin's capital strength, accelerate the development of innovative drugs, and improve talent attraction and research efficiency [3]